Mineralys Therapeutics, Inc.
MLYS
$25.02
-$0.71-2.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -154.65M | -171.36M | -190.77M | -188.51M | -177.81M |
| Total Depreciation and Amortization | 59.00K | 61.00K | 57.00K | 50.00K | 43.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.45M | 10.17M | 7.15M | 4.85M | 1.93M |
| Change in Net Operating Assets | 2.73M | -10.23M | -9.12M | -9.05M | 9.52M |
| Cash from Operations | -142.42M | -171.37M | -192.69M | -192.66M | -166.31M |
| Capital Expenditure | -15.00K | 0.00 | -37.00K | -37.00K | -96.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -389.74M | -202.69M | 27.46M | 78.07M | 115.06M |
| Cash from Investing | -389.75M | -202.69M | 27.42M | 78.04M | 114.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 591.39M | 494.52M | 199.34M | 189.60M | 116.58M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -391.00K | -133.00K | -145.00K | -382.00K | -435.00K |
| Cash from Financing | 591.00M | 494.39M | 199.20M | 189.22M | 116.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.83M | 120.32M | 33.93M | 74.59M | 64.79M |